Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy

Liver International

Volumn 23, Issue 4, 2003, Pages 269-275

  Steindl Munda, Petra ^a   Ferenci, Peter ^a   Brunner, Harald ^b   Nachbaur, Karin ^c   Datz, Christian ^d   Gschwantler, Michael ^e   Hofer, Harald ^a   Stauber, Rudolf ^f   Hackl, Franz ^g   Jessner, Wolfgang ^a   Rosenbeiger, Martha ^b   Gangl, Alfred ^a   Vogel, Wolfgang ^c   Hofer, H ^a   Jessner, W ^a   Gangl, A ^a   Muller C ^a   Osterreicher C ^a   Novacek, G ^a   Penner, E ^a   Peck Radosavljevic, M ^a   Hentschel, E ^h   Scharf, C ^h   Schutze W ^h   Hartmann, G ⁱ   Sebesta, E C ⁱ   Gschwantler, M ^j   Bognar, K ^b   Brunner, H ^b   Kopty, C ^b   Rosenbeiger, M ^b   Dragosics, B ^k   Hackl, F ^g   Hubmann, R ^l   Buder, R ^m   Nitsche, D ⁿ   Marzy, H ^o   Haidinger, R ^o   Schneeweiss, B ^o   Renner, F ^o   Allinger, S ^o   Knoflach, P ^o   Stadler, B ^o   Stetter, M ^o   Datz, C ^d   Raffelsberger, R ^d   Herrman, R ^o   Stingl, W ^o   Begic Karup, S ^o   Jaritz, B ^o   Kutilek, M ^o   Ptacek Wegerer, K ^o   Goldsteiner, H ^o   Kotlan, P ^o   Taschner, H ^o   Spahits, E ^o   Stockenhuber, F ^o   Stangl, W ^o   Fickert, P ^f   Hegenbarth, K ^f   Krejs, G J ^f   Stauber, R ^f   Trauner, M ^f   Bauer, B ^o   Rainer, W ^o   Pristautz, H ^o   Edis, G C ^c   Nachbaur, K ^c   Erhart, K ^o   Dertinger, S ^o   Reichsollner F ^o   Eritscher Tinhofer, C W ^o   Grimm, G ^o   Turk H ^o   Siebert, F ^o   Lin, W ^o   Hoffmann, H ^a   Watkins Riedl, Th ^a   Kessler, H ^o   Wrba, F ^a   Denk, H ^o   Offner, F ^o   Dietze, O ^o   Neumann, K ^o   Frommlet, F ^o   more..

^a UNIVERSITY OF VIENNA   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d St Johanns Spital   (Austria)

^e KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^f UNIVERSITY OF GRAZ   (Austria)

^g ELISABETHINEN HOSPITAL   (Austria)

^h HANUSCH HOSPITAL   (Austria)

ⁱ DANUBE HOSPITAL   (Austria)

^j Rudolf Foundation Hospital   (Austria)

^k Gesundheitszentrum SÜd   (Austria)

^l KEPLER UNIVERSITY HOSPITAL   (Austria)

^m KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

ⁿ Krankenhaus der Barmherzige Schwestern   (Austria)

^o Barmherzige Brüder ^*

more..

Author keywords

Hepatitis C; High dose induction therapy; Nonresponders; Relapsers

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0142092760     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2003.00838.x     Document Type: Article

References (33)

1. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89.
2. Alberti A, Chemello L, Noventa F, et al. Therapy of hepatitis C: Re-treatment with alpha interferon. Hepatology 1997; 26(Suppl. 1): S137-42.
3. McHutchison J G, Gordon S C, Schiff E R, Shiffman M L, Lee W M, Rustgi V K, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
4. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
5. Davis G L, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-99.
6. Brouwer J T, Nevens F, Michielsen P, et al. What options are left when hepatitis C does not respond to interferon? Placebo controlled Benelux multicentre trial on ribavirin mono-therapy versus prolonged combination with interferon. J Hepatol 1994; 21: S17-9.
7. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995; 23(Suppl. 2): 13-6.
8. Ferenci P, Stauber R, Steindl-Munda P, Gschwandtler M, Fickert P, Datz Ch, et al. Treatment of patients with chronic hepatitis C not responsive to interferon with high-dose interferon-alfa with or without ribavirin: results of a prospective randomized trial. Eur J Gastrol Hepatol 2001; 13: 1-7.
9. Schvarcz R, Ando Y, Sonnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin in patients who failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995; 23(Suppl. 2): 17-21.
10. Neumann A U, Lam N P, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon- therapy. Science 1998; 282: 103-7.
11. Ferenci P, Brunner H, Nachbauer K, Datz Ch, Gschwantler M, Hofer H, et al. Combination of Interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001; 34: 1006-11.
12. Jessner W, Gschwantler M, Steindl-Munda P, Hofer H, Watkins-Riedel T, Wrba F, Mueller C, Gandl A, Ferenci P. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001; 358: 1241-42.
13. EASL International Consensus Conference on Hepatitis C Consensus Statement. J Hepatol 1999; 30: 956-61.
14. Ferenci P, Renner F, Müller Ch, et al. Empfehlungen zur Behandlung der Virushepatitis. Konsensus - Konferenz der ÖGGH. Z Gastroenterol 1999; 37: 21-7.
15. Di Bisceglie A M, Thompson J, Smith-Wilkaitis N, Brunt E M, Bacon B R. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001; 33: 704-7.
16. Kallinowski B, Liehr H, Moeller B, Stremmel W, Wechsler J G, Wiese M, Goeser T. Combination therapy with interferon-alpha2b and ribavirin for the treatment of relapse patients and non-responders with chronic HCV infection. Z Gastroenterol 2001; 39: 199-204.
17. Younossi Z M, Mullen K D, Zakko W, Hodnick S, Brand E, Barnes D S, et al. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy. J Hepatol 2001; 34: 128-33.
18. Cozzolongo R, Cuppone R, Giannuzzi V, Amati L, Caradonna L. Tamborrino V, Jirillo E, Manghisi O G. Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon. Aliment Pharmacol Ther 2001; 15: 129-35.
19. Milella M, Santantonio T, Pietromatera G, Maselli R, Casalino C, Mariano N, Genchi C, Pastore G. Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone. Ital J Gastroenterol Hepatol 1999; 31: 211-15.
20. Saracco G, Ciancio A, Olivero A, Smedile A. Roffi L, Croce G, et al. A randomized 4-Arm multicenter study of interferon alfa-2B plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 2001; 34: 133-38.
21. Marco V D, Almasio P, Vaccaro A, Ferraro D, Parisi P, Cataldo M G, Di Stefano R, Craxi A. Combined treatment of relapse of chronic hepatitis C with high-dose alpha 2b interferon plus ribavirin for 6 or 12 months. J Hepatol 2000; 33: 456-62.
22. Lo Iacono O, Castro A. Diago M, Moreno J A, Fernandez-Bermejo M, Vega P, et al. Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy. Aliment Pharmacol Ther 2000; 14: 463-69.
23. Enriquez J, Gallego A, Torras X, Perez-Olmeda T, Diado M, Soriano V, Lujan M S, Garcia-Samaniego J. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J Viral Hepat 2000; 7: 403-8.
24. Cavaletto L. Chemello L, Donado C, Casarin P, Belussi F, Bernardinello E, Marino F, et al. The pattern of response to interferon alpha (IFN) predicts sustained response to a 6-month IFN and ribavirin retreatment for chronic hepatitis C. J Hepatol 2000; 33: 128-34.
25. Pol S, Couzigou P, Bourliere M, Abergel A, Combis J-M, Larrey D, Tran A. et al. A randomized trial of ribavirin and interferon - vs interferon-alone in patients with chronic hepatitis C who were non-responders to a previous treatment. J Hepatol 1999; 31: 1-7.
26. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Bellomo G, Belloni G. Grisorio B, et al. Interferon-á2b and ribavirin in combination for chronic hepatitis C patients not responding to interferon-a alone: an Italian multicenter, randomized, controlled, clinical study. Am J Gastroenterol 1998; 93: 2445-51.
27. De Ledinghen V, Trimoulet P, Winnock M, Bernard P H, Bourliere M, Portal I, et al. Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone. J Hepatol 2002; 36: 819-26.
28. National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 1997; 26 (Suppl. 1): 2S-10S.
29. Bekkering F C, Stalgis C, McHutchinson J G, Brouwer J T, Perelson A S. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001; 33: 419-23.
30. McHutchison J G, Shad J A. Gordon S C, Morgan T R, Ling M H, Garaud JJ, Albrecht J K, Dienstag J L. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepatitis 2001; 8: 414-20.
31. Ferenci P, Shiffman M L, Fried M W, et al. Early prediction of response to 40 kDa peginterferon alfa-2a (PEGASYS®) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC). Hepatology 2001; 34: 351A.
32. Ferenci P, Dragosics P, Pauser G. Non-A-Non-B-Hepatitisepidemie bei einer Plasmapheresestelle. Verh. Dtsch. Ges. Inn. Med. 1979; 85: 553-6.
33. Datz C, Cramp M, Haas T, Dietze O, Nitschko H, Froesner G, Muss N, Sandhofer F, Vogel W. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut 1999; 44: 563-7.